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OBJECTIVES: To assess clinical efficacy and cost-effectiveness of human recombi-
nant interferon-2b in neonates with intrauterine infections in neonatal intensive
care unit (NICU). METHODS: We observed 151 neonates (gestational age (GA) 25-40
weeks) with severe intrauterine infections in NICU. Group 1 included 94 neonates
with severe intrauterine infections treated with interferon-2b, 150 000 IU per
suppositorium twice a day per rectum during 7 days in addition to combined anti-
bacterial and supportive therapy; group 2 consisted of 57 neonates under standard
treatment without additional immunotherapy. Initially neonates of both groups
were comparable. Effectiveness data were used to populate a decision model to
estimate the cost-effectiveness of interferon-2b and standard therapy. Direct and
indirect costs were measured. Published cost data were applied to assess differ-
ences in treatment costs. RESULTS: Low mitogen-induced interferon- production
(12 pg/ml) was detected in 25% [18%; 33%] of neonates with severe intrauterine
infections, its association with significantly higher incidence of pneumonia
(0.001), necrotizing enterocolitis (0.001) and urinary tract infections (0.026)
was proved. Administration of human recombinant interferon-2b to neonates,
suffering from severe infections, provides improvement of mitogen-induced pro-
duction of interferon-, reduces hospital length of stay and mortality rates
(0.009, OR 0.21 [0.05; 0.67], RR 0.26 [0.07; 0.69], NNT8 [4; 29]). Interferon-2b
administration for severe early-onset neonatal infections decreases direct costs
per patient by 20% (direct costs per patient € 6,802 and € 8,549 for interferon-2b
and control groups, respectively). Interferon-2b administration for intrauterine
infections leads to substantial cost savings (up to € 69,247 per patient).
CONCLUSIONS: Immunotherapy with interferon-2b is a cost-effective interven-
tion improves the clinical course and outcome in case of severe intrauterine infec-
tions.
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OBJECTIVES: Several published studies have demonstrated that the supplementa-
tion of Omegaven® has better clinical outcomes in Systemic Inflammatory Re-
sponse Syndrome (SIRS) or elective major surgery patients treated in Intensive Care
Units (ICUs),with shorter average lengths of stay in hospital and reduced fatality
rate , as compared to standard total parenteral nutrition (TPN) regimens. The ob-
jective of the simulation study was to evaluate the CE of the supplementation of
Omegaven® vs standard TPN in the Chinese setting. METHODS: A discrete event
simulation (DES) model was constructed to compare the nutritional strategies in
elective surgery and SIRS patients, by combining outcomes recorded in 79 elective
major surgical patients and 56 SIRS patients receiving TPN in the surgical ICU of a
tertiary hospital in Shanghai. Omegaven® efficacy estimates from a random effects
Bayesian meta-analysis on Chinese and international clinical trials, and Chinese
cost data collected in the same hospital, comprising ICU and general ward costs,
and the cost for TPN. RESULTS: Omegaven® showed being effective in reducing
fatality rate and total hospital length of stay (- 2.8 and -2.5 days) in both surgical and
SIRS patients. In the SIRS group, the treatment could avoid 5.7 deaths every 100
patients. Reduced hospitalizations costs completely offset treatment cost, with a
saving associated with Omegaven® of about 8,000 and 6,800 RMB in surgical and
SIRS patients, respectively. CONCLUSIONS: The supplementation of Omegaven®
can be considered dominant versus standard TPN, as the results of DES show that
a mean increase of the effectiveness is associated with a mean decrease of the
costs.
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OBJECTIVES: Ulipristal acetate - a selective progesterone receptor modulator - was
proved to be effective for 3 month pre-operative treatment of moderate to severe
symptoms of uterine fibroids in adult women of reproductive age. The aim of this
analysis was to assess the cost-effectiveness of ulipristal acetate 5 mg as an add-on
therapy to standard pre-surgical treatment in Hungary. METHODS: A Markov
state-transition economic model was developed over 10 year time horizon. Ulip-
ristal acetate was compared to 1) pre-surgical observation, and 2) immediate hys-
terectomy. The model comprises mutually exclusive health states: no/mild bleed-
ing disorder, heavy bleeding disorder, persistent heavy bleeding disorder,
myomectomy, post-myomectomy with no/mild bleeding disorder, post-myomec-
tomy with heavy bleeding disorder, hysterectomy, post-hysterectomy, post-meno-
pausa and death. Transition probabilities and utility values were drawn from the
Pearl I clinical trial and scientific literature. Resource utilisation and unit costs were
derived from the consensus panel of clinical experts and National Health Insurance
Fund tariffs and publications. Costs and QALYs were discounted at a yearly rate of
3.5%. RESULTS: Addition of 3 month ulipristal acetate to the standard pre-opera-
tive therapy was predicted to achieve an additional 0.019 QALYs compared to ob-
servation at an estimated incremental cost of €376, resulting an incremental cost of
20,180 €/QALY. Results were most sensitive to the utility value of post-hysterec-
tomy, but robust to changes in further model parameters. When 3 month of ther-
apy was compared to immediate hysterectomy without any observation period,
the ICER was reduced to 6,095 €/QALY. CONCLUSIONS: The analysis suggests that
adding ulipristal acetate treatment to standard pre-surgical therapy represents
good value for money according to currently accepted cost-effectiveness criterion
in Hungary. Inclusion of societal benefits may considerably reduce the cost-effec-
tiveness ratio, however further evidence from observational studies is needed to
capture potential benefits of ulipristal acetate therapy on fertility.
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OBJECTIVES: Testosterone replacement therapy (TRT) is recommended for the
treatment of primary and secondary hypogonadism. However, long-term implica-
tions of this therapy have not been investigated extensively. Therefore, the aim of
this analysis was to evaluate health outcomes and costs associated with life-long
TRT in patients suffering from Klinefelter syndrome and late-onset hypogonadism
(LOH). METHODS: A Markov model was developed to assess cost-effectiveness of
testosterone undecanoate (TU) depot injection treatment compared with no treat-
ment. Health outcomes and associated costs were modeled in monthly cycles per
each patient individually along life-time horizon. Modeled health scenarios in-
cluded development of type 2 diabetes, depression, cardiovascular and cerebrovas-
cular complications and fractures. Results were expressed in terms of incremental
quality of life years (QALY) gained, incremental costs and incremental cost-effec-
tiveness ratio (ICER). Analysis was performed for the Swedish health care settings
from health care payer’s and societal perspective. One way sensitivity analyses
served to evaluate robustness of the results. RESULTS: TU depot injection in
Klinefelter population yielded a gain of 1.67 QALYs compared to the no-treatment
at an incremental cost of 257,757 SEK (28,176 EUR), showing an ICER of 154,459 SEK
(16,884 EUR) per QALY gained. Outcomes in LOH population estimated benefits of
TRT at 180,400 SEK (19,719 EUR) per QALY gained. Results showed to be consider-
ably robust when tested in sensitivity analysis. Variation of relative risk to develop
type 2 diabetes had the highest impact on long-term outcomes in both patient
groups. CONCLUSIONS: TRT treatment proved its efficacy across many clinical
trials. This analysis suggests that life-long TU depot injection therapy is cost-effec-
tive in Sweden for patients with hypogonadism. Hence, it can support clinicians in
decision making when considering appropriate treatment strategies for patients
with testosterone deficiency.
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OBJECTIVES: The assessment of indirect costs represents an extremely important
issue when managing chronic diseases. Patients’ lost productivity is often over-
looked by decison makers, although it is fundamental for the complete estimation
of the true economic impact of disease. The objective of this study is to estimate the
social savings obtained with Adalimumab compared to standard therapies for the
treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,
Crohn’s disease and psoriasis, in the Italian population. METHODS: Five different
economic models have been developed to estimate the cost utility of Adalimumab
vs standard care for each of the diseases (the economic models were developed by
external consultants). Both Italian National Health System (direct costs) and social
(direct costs loss of productivity) perspectives were adopted. For each pathology
models have calculated the loss of productivity per pt/year with standard therapy
and with Adalimumab. A sensitivity analysis, based on the variability of model
parameters, was performed in order to assess the robustness of the results.
RESULTS: In the base case scenario, the average annual social cost (weighted for
prevalence of eligible patients for biologic treatment of each pathology) per patient
amounted to €1274,25 if treated with standard care, compared with €569,48 if
treated with Adalimumab. Adalimumab treatment would allow –9,4% (€42 mil-
lions) reduction of the total social cost assuming 17% of market penetration for
patients eligible for biologic use. Sensitivity analysis shows that annual saving in
social costs can vary from 8,1 to 11,9% assuming an average market share of 17% of
Adalimumab. CONCLUSIONS: Adalimumab has a significant impact in reducing
social costs for all the diseases considered in this study. These aspects, often ne-
glected in decision makers’ assessments, should instead be included in the overall
evaluation of benefits, of innovative technologies as biologic drugs.
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OBJECTIVES: Parenteral nutrition (PN) is critical in neonatal and pediatric care for
patients unable to tolerate enteral feeding. Considering the limited cost data on
pediatric PN in Belgium, the aim of this study was to evaluate total Belgian PN costs
when admixtures are produced in-hospital, either in a pharmacy or in the ward.
METHODS: A cost-model was used to assess the following: nutrient costs; labor
costs (personnel costs to prescribe and prepare); disposable costs (supplies used);
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